-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
2
-
-
12944271053
-
Cancer statistics, 2005
-
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 10-30
-
-
Jemal, A.1
Murray, T.2
Ward, E.3
-
3
-
-
1342268525
-
American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003
-
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
-
(2004)
J Clin Oncol
, vol.22
, pp. 330-353
-
-
Pfister, D.G.1
Johnson, D.H.2
Azzoli, C.G.3
-
5
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small cell lung cancer
-
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
-
(2002)
N Engl J Med
, vol.346
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
-
6
-
-
0037529167
-
The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer
-
Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am 2003;9:207-36.
-
(2003)
Respir Care Clin N Am
, vol.9
, pp. 207-236
-
-
Socinski, M.A.1
-
7
-
-
0037037386
-
Platinum drugs in the treatment of non-small-cell lung cancer
-
Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002;87:825-33.
-
(2002)
Br J Cancer
, vol.87
, pp. 825-833
-
-
Cosaert, J.1
Quoix, E.2
-
8
-
-
21144436938
-
Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel
-
Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-37.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3125-3137
-
-
Gridelli, C.1
Aapro, M.2
Ardizzoni, A.3
-
9
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
-
10
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues RJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues, R.J.2
Ciuleanu, T.3
-
11
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
-
12
-
-
4444238981
-
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]
-
Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. J Clin Oncol 2004;22:7010.
-
(2004)
J Clin Oncol
, vol.22
, pp. 7010
-
-
Gatzemeier, U.1
Pluzanska, A.2
Szczesna, A.3
-
13
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
-
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT1. J Clin Oncol 2004;22:777-84.
-
(2004)
J Clin Oncol
, vol.22
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
-
14
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
-
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-94.
-
(2004)
J Clin Oncol
, vol.22
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
-
15
-
-
0026846928
-
The role of angiogenesis in tumor growth
-
Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 2002;3:65-71.
-
(2002)
Semin Cancer Biol
, vol.3
, pp. 65-71
-
-
Folkman, J.1
-
16
-
-
0036780251
-
Clinical translation of angiogenesis inhibitors
-
Kerbel RS, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 727-739
-
-
Kerbel, R.S.1
Folkman, J.2
-
17
-
-
0242637170
-
Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer
-
Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003;42 Suppl 1:S81-91.
-
(2003)
Lung Cancer
, vol.42
, Issue.SUPPL. 1
-
-
Sridhar, S.S.1
Shepherd, F.A.2
-
18
-
-
0842329999
-
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
-
Eskens FALM. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1-7.
-
(2004)
Br J Cancer
, vol.90
, pp. 1-7
-
-
Eskens, F.A.L.M.1
-
19
-
-
12244292196
-
Differentiation and definition of vascular-targeted therapies
-
Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-20.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 416-420
-
-
Siemann, D.W.1
Bibby, M.C.2
Dark, G.G.3
-
20
-
-
33646676706
-
Antiangiogenic drugs in non-small cell lung cancer treatment
-
Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol 2006;18:151-5.
-
(2006)
Curr Opin Oncol
, vol.18
, pp. 151-155
-
-
Cascone, T.1
Troiani, T.2
Morelli, M.P.3
Gridelli, C.4
Ciardiello, F.5
-
21
-
-
33745934672
-
Angiogenesis inhibitors in lung cancer: A promise fulfilled
-
Dy GK, Adjei AA. Angiogenesis inhibitors in lung cancer: a promise fulfilled. Clin Lung Cancer 2006;7 Suppl 4:S145-9.
-
(2006)
Clin Lung Cancer
, vol.7
, Issue.SUPPL. 4
-
-
Dy, G.K.1
Adjei, A.A.2
-
22
-
-
0037967272
-
Tumorigenesis and the angiogenic switch
-
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 401-410
-
-
Bergers, G.1
Benjamin, L.E.2
-
23
-
-
4143136640
-
Vascular endothelial growth factor: Basic science and clinical progress
-
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
-
(2004)
Endocr Rev
, vol.25
, pp. 581-611
-
-
Ferrara, N.1
-
25
-
-
2942590261
-
Vascular endothelial growth factor as a target for anticancer therapy
-
Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 Suppl 1:2-10.
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 1
, pp. 2-10
-
-
Ferrara, N.1
-
26
-
-
1842328560
-
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer
-
Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-8.
-
(1997)
Int J Cancer
, vol.74
, pp. 64-68
-
-
Volm, M.1
Koomagi, R.2
Mattern, J.3
-
27
-
-
0031966682
-
Vascular endothelial growth factor expression in non-small cell lung cancer: Prognostic significance in squamous cell carcinoma
-
Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115:1007-14.
-
(1998)
J Thorac Cardiovasc Surg
, vol.115
, pp. 1007-1014
-
-
Imoto, H.1
Osaki, T.2
Taga, S.3
Ohgami, A.4
Ichiyoshi, Y.5
Yasumoto, K.6
-
28
-
-
0034024352
-
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer
-
O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br J Cancer 2000;82:1427-32.
-
(2000)
Br J Cancer
, vol.82
, pp. 1427-1432
-
-
O'Byrne, K.J.1
Koukourakis, M.I.2
Giatromanolaki, A.3
-
29
-
-
0035155064
-
Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis
-
Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72-9.
-
(2001)
Ann Surg Oncol
, vol.8
, pp. 72-79
-
-
Han, H.1
Silverman, J.F.2
Santucci, T.S.3
-
30
-
-
0035863288
-
Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small cell lung cancer
-
Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small cell lung cancer. J Clin Oncol 2001;19:432-41.
-
(2001)
J Clin Oncol
, vol.19
, pp. 432-441
-
-
Yuan, A.1
Yu, C.J.2
Kuo, S.H.3
-
31
-
-
18244364180
-
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma
-
Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-63.
-
(2002)
Br J Cancer
, vol.86
, pp. 558-563
-
-
Fontanini, G.1
Faviana, P.2
Lucchi, M.3
-
32
-
-
3242700400
-
The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients
-
Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004;98:632-6.
-
(2004)
Respir Med
, vol.98
, pp. 632-636
-
-
Kaya, A.1
Ciledag, A.2
Gulbay, B.E.3
-
33
-
-
19844380545
-
Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer
-
Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183:29-42.
-
(2005)
Lung
, vol.183
, pp. 29-42
-
-
Shimanuki, Y.1
Takahashi, K.2
Cui, R.3
-
34
-
-
0037626575
-
Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules
-
Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003;94:479-85.
-
(2003)
Cancer Sci
, vol.94
, pp. 479-485
-
-
Yano, S.1
Nishioka, Y.2
Goto, H.3
Sone, S.4
-
35
-
-
3843135260
-
Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs)
-
Ishii H, Yazawa T, Sato H, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 2004;45:325-37.
-
(2004)
Lung Cancer
, vol.45
, pp. 325-337
-
-
Ishii, H.1
Yazawa, T.2
Sato, H.3
-
36
-
-
0000748868
-
The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract 2906]
-
Kabbinavar FF, Wong JT, Ayala RE, et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract 2906]. Proc Am Assoc Cancer Res 1995;36:488.
-
(1995)
Proc Am Assoc Cancer Res
, vol.36
, pp. 488
-
-
Kabbinavar, F.F.1
Wong, J.T.2
Ayala, R.E.3
-
37
-
-
0034665166
-
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
-
Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.
-
(2000)
Cancer Res
, vol.60
, pp. 5117-5124
-
-
Brekken, R.A.1
Overholser, J.P.2
Stastny, V.A.3
Waltenberger, J.4
Minna, J.D.5
Thorpe, P.E.6
-
38
-
-
9144265679
-
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects
-
Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63:8890-8.
-
(2003)
Cancer Res
, vol.63
, pp. 8890-8898
-
-
Abdollahi, A.1
Lipson, K.E.2
Sckell, A.3
-
39
-
-
2442708026
-
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor
-
Sun J, Blaskovich MA, Jain RK, et al. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 2004;64:3586-92.
-
(2004)
Cancer Res
, vol.64
, pp. 3586-3592
-
-
Sun, J.1
Blaskovich, M.A.2
Jain, R.K.3
-
40
-
-
12344263868
-
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth
-
Nakamura K, Yamamoto A, Kamishohara M, et al. KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther 2004;3:1639-49.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 1639-1649
-
-
Nakamura, K.1
Yamamoto, A.2
Kamishohara, M.3
-
41
-
-
3042803907
-
A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth
-
Ueda Y, Yamagishi T, Samata K, et al. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth. Cancer Chemother Pharmacol 2004;54:16-24.
-
(2004)
Cancer Chemother Pharmacol
, vol.54
, pp. 16-24
-
-
Ueda, Y.1
Yamagishi, T.2
Samata, K.3
-
42
-
-
0034655246
-
Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
-
Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000;60:2169-77.
-
(2000)
Cancer Res
, vol.60
, pp. 2169-2177
-
-
Takayama, K.1
Ueno, H.2
Nakanishi, Y.3
-
43
-
-
0036006171
-
Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy
-
Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280-3.
-
(2002)
Bioessays
, vol.24
, pp. 280-283
-
-
Harmey, J.H.1
Bouchier-Hayes, D.2
-
44
-
-
20544471876
-
Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
-
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3706-3712
-
-
Kabbinavar, F.F.1
Hambleton, J.2
Mass, R.D.3
Hurwitz, H.I.4
Bergsland, E.5
Sarkar, S.6
-
45
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
46
-
-
28044467635
-
Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract 4000]
-
Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract 4000]. J Clin Oncol 2005;23:308S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Demetri, G.D.1
van Oosterom, A.T.2
Blackstein, M.3
-
47
-
-
23844558595
-
Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract LBA4510]
-
Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract LBA4510]. J Clin Oncol 2005;23:380S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Escudier, B.1
Szczylik, C.2
Eisen, T.3
-
48
-
-
21244481589
-
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the eastern cooperative oncology group (ECOG) study E3200 [abstract 2]
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the eastern cooperative oncology group (ECOG) study E3200 [abstract 2]. J Clin Oncol 2005;23:1S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
49
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
-
(1997)
Cancer Res
, vol.57
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
-
50
-
-
2942526896
-
Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab?
-
Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 2004;9:19-26.
-
(2004)
Oncologist
, vol.9
, pp. 19-26
-
-
Herbst, R.S.1
Sandler, A.B.2
-
51
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
-
(2003)
N Engl J Med
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
-
52
-
-
33644984682
-
First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: A randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract 275]
-
Miller K, Wang M, Gralow J, et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract 275]. Eur J Cancer Suppl 2005;3:77.
-
(2005)
Eur J Cancer Suppl
, vol.3
, pp. 77
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
53
-
-
2942657615
-
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
-
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2184-2191
-
-
Johnson, D.H.1
Fehrenbacher, L.2
Novotny, W.F.3
-
54
-
-
22144471081
-
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599 [abstract LBA4]
-
Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599 [abstract LBA4]. J Clin Oncol 2005;23:2S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Sandler, A.B.1
Gray, R.2
Brahmer, J.3
-
55
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
56
-
-
28044434570
-
A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) [abstract 3067]
-
Adjei AA, Mandrekar S, Marks RS, et al. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) [abstract 3067]. J Clin Oncol 2005;23:208S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Adjei, A.A.1
Mandrekar, S.2
Marks, R.S.3
-
57
-
-
33748913369
-
Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma [abstract 7002]
-
Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma [abstract 7002]. J Clin Oncol 2006;24:7002.
-
(2006)
J Clin Oncol
, vol.24
, pp. 7002
-
-
Gatzemeier, U.1
Blumenschein, G.2
Fosella, F.3
-
58
-
-
78650874372
-
SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer
-
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
Pryer, N.K.4
Cherrington, J.M.5
-
59
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
-
(2003)
Blood
, vol.101
, pp. 3597-3605
-
-
O'Farrell, A.M.1
Abrams, T.J.2
Yuen, H.A.3
-
60
-
-
12444297983
-
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
-
Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225-33.
-
(2004)
Angiogenesis
, vol.7
, pp. 225-233
-
-
Osusky, K.L.1
Hallahan, D.E.2
Fu, A.3
Ye, F.4
Shyr, Y.5
Geng, L.6
-
61
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
-
62
-
-
0041672482
-
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models
-
Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-16.
-
(2003)
Cancer Res
, vol.63
, pp. 4009-4016
-
-
Schueneman, A.J.1
Himmelfarb, E.2
Geng, L.3
-
63
-
-
33644833910
-
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
-
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
-
(2006)
J Clin Oncol
, vol.24
, pp. 16-24
-
-
Motzer, R.J.1
Michaelson, M.D.2
Redman, B.G.3
-
64
-
-
0034655182
-
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
-
Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
-
(2000)
Cancer Res
, vol.60
, pp. 2178-2189
-
-
Wood, J.M.1
Bold, G.2
Buchdunger, E.3
-
65
-
-
0034016273
-
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
-
Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000;6:957-65.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 957-965
-
-
Yano, S.1
Herbst, R.S.2
Shinohara, H.3
-
66
-
-
23044432756
-
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
-
Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162-71.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4162-4171
-
-
Thomas, A.L.1
Morgan, B.2
Horsfield, M.A.3
-
67
-
-
23844548194
-
A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract LBA3]
-
Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract LBA3]. J Clin Oncol 2005;23:2S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Hecht, J.R.1
Trarbach, T.2
Jaeger, E.3
-
68
-
-
33749637207
-
Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM-2) [abstract 3508]
-
Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM-2) [abstract 3508]. J Clin Oncol 2006;24:3508.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3508
-
-
Koehne, C.1
Bajetta, E.2
Lin, E.3
-
69
-
-
32044469735
-
The effect of AMG 706, a novel multi-kinase inhibitor, on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model [abstract 3134]
-
Jackson E, Esparza-Coss E, Bankson JA, et al. The effect of AMG 706, a novel multi-kinase inhibitor, on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model [abstract 3134]. J Clin Oncol 2005;23:225S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Jackson, E.1
Esparza-Coss, E.2
Bankson, J.A.3
-
70
-
-
10744222964
-
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy
-
Beebe JS, Jani JP, Knauth E, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003;63:7301-9.
-
(2003)
Cancer Res
, vol.63
, pp. 7301-7309
-
-
Beebe, J.S.1
Jani, J.P.2
Knauth, E.3
-
71
-
-
34247472705
-
Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) [abstract 3014]
-
Cohen RB, Simon G, Langer CJ, et al. Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) [abstract 3014]. J Clin Oncol 2004;22:14S.
-
(2004)
J Clin Oncol
, vol.22
-
-
Cohen, R.B.1
Simon, G.2
Langer, C.J.3
-
72
-
-
20144370978
-
AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
-
Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400.
-
(2005)
Cancer Res
, vol.65
, pp. 4389-4400
-
-
Wedge, S.R.1
Kendrew, J.2
Hennequin, L.F.3
-
73
-
-
33751414107
-
Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [abstract 3054]
-
Laurie SA, Arnold A, Gauthier I, et al. Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [abstract 3054]. J Clin Oncol 2006;24:3054.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3054
-
-
Laurie, S.A.1
Arnold, A.2
Gauthier, I.3
-
74
-
-
0037934449
-
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
-
Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003;100:7785-90.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 7785-7790
-
-
Huang, J.1
Frischer, J.S.2
Serur, A.3
-
75
-
-
33746316839
-
Phase II study of carboplatin, irinotecan and thalidomide in patients with advanced non-small cell lung cancer (NSCLC) [abstract 7132]
-
Miller AA, Case D, Atkins J, Giguere J. Phase II study of carboplatin, irinotecan and thalidomide in patients with advanced non-small cell lung cancer (NSCLC) [abstract 7132]. J Clin Oncol 2004;22:649S.
-
(2004)
J Clin Oncol
, vol.22
-
-
Miller, A.A.1
Case, D.2
Atkins, J.3
Giguere, J.4
-
76
-
-
34247529580
-
-
Flora DB, Kleykamp B, Knapp M, Shukla R, Jazieh AR. A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract 7258]. J Clin Oncol 2004;22:680-S.
-
Flora DB, Kleykamp B, Knapp M, Shukla R, Jazieh AR. A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract 7258]. J Clin Oncol 2004;22:680-S.
-
-
-
-
77
-
-
0033818695
-
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
-
Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3739-3747
-
-
Ciardiello, F.1
Bianco, R.2
Damiano, V.3
-
78
-
-
17944370631
-
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
-
Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-9.
-
(2001)
Br J Cancer
, vol.85
, pp. 584-589
-
-
Shaheen, R.M.1
Ahmad, S.A.2
Liu, W.3
-
79
-
-
0036252329
-
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model
-
Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-40.
-
(2002)
Eur J Cancer
, vol.38
, pp. 1133-1140
-
-
Jung, Y.D.1
Mansfield, P.F.2
Akagi, M.3
-
80
-
-
5044236157
-
Epidermal growth factor receptor in tumor angiogenesis
-
viii
-
Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:1007-21, viii.
-
(2004)
Hematol Oncol Clin North Am
, vol.18
, pp. 1007-1021
-
-
Ellis, L.M.1
-
81
-
-
28044433677
-
Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies
-
van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005;117:883-8.
-
(2005)
Int J Cancer
, vol.117
, pp. 883-888
-
-
van Cruijsen, H.1
Giaccone, G.2
Hoekman, K.3
-
82
-
-
1242270612
-
Acquired resistance to EGFR inhibitors: Mechanisms and prevention strategies
-
Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 2004;58:914-26.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 914-926
-
-
Viloria-Petit, A.M.1
Kerbel, R.S.2
-
83
-
-
34247518783
-
Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: Discovery and in vitro profile of AEE788 [abstract A118]
-
Caravatti G, Bold G, Bruggen J, et al. Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: discovery and in vitro profile of AEE788 [abstract A118]. Clin Cancer Res 2003;9:16.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 16
-
-
Caravatti, G.1
Bold, G.2
Bruggen, J.3
-
84
-
-
34247518783
-
Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: In vivo profile of AEE788 [abstract A87]
-
Traxler P, Allegrini PR, Brandt R, et al. Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: in vivo profile of AEE788 [abstract A87]. Clin Cancer Res 2003;9 Suppl 1:16.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.SUPPL. 1
, pp. 16
-
-
Traxler, P.1
Allegrini, P.R.2
Brandt, R.3
-
85
-
-
28044436878
-
A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients [abstract 3063]
-
Reardon D, Cloughesy T, Conrad C, et al. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients [abstract 3063]. Proc Am Soc Clin Oncol 2005;24:3063.
-
(2005)
Proc Am Soc Clin Oncol
, vol.24
, pp. 3063
-
-
Reardon, D.1
Cloughesy, T.2
Conrad, C.3
-
86
-
-
0037386774
-
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
-
Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1546-1556
-
-
Ciardiello, F.1
Caputo, R.2
Damiano, V.3
-
87
-
-
0037102369
-
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
-
Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
-
(2002)
Cancer Res
, vol.62
, pp. 4645-4655
-
-
Wedge, S.R.1
Ogilvie, D.J.2
Dukes, M.3
-
88
-
-
10844285939
-
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models
-
Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci 2004;95:984-9.
-
(2004)
Cancer Sci
, vol.95
, pp. 984-989
-
-
Taguchi, F.1
Koh, Y.2
Koizumi, F.3
Tamura, T.4
Saijo, N.5
Nishio, K.6
-
89
-
-
23844544081
-
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
-
Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7.
-
(2005)
Ann Oncol
, vol.16
, pp. 1391-1397
-
-
Holden, S.N.1
Eckhardt, S.G.2
Basser, R.3
-
90
-
-
29244480558
-
A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract 3023]
-
Heymach JV, Johnson BE, Rowbottom JA, et al. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract 3023]. J Clin Oncol 2005;23:197S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Heymach, J.V.1
Johnson, B.E.2
Rowbottom, J.A.3
-
91
-
-
21244501441
-
Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC [abstract 7102]
-
Johnson BE, Ma P, West H, et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC [abstract 7102]. J Clin Oncol 2005;23:645S.
-
(2005)
J Clin Oncol
, vol.23
-
-
Johnson, B.E.1
Ma, P.2
West, H.3
-
92
-
-
33644982526
-
Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC [abstract 1124]
-
Ranson M, Bodkin D, Govindan R, et al. Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC [abstract 1124]. Eur J Cancer Suppl 2005;3:324.
-
(2005)
Eur J Cancer Suppl
, vol.3
, pp. 324
-
-
Ranson, M.1
Bodkin, D.2
Govindan, R.3
-
93
-
-
20244381389
-
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
-
Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2544-2555
-
-
Herbst, R.S.1
Johnson, D.H.2
Mininberg, E.3
-
94
-
-
34247467122
-
A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer [abstract 53]
-
Herbst RS, Fehrenbacher L, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer [abstract 53]. Eur J Cancer Suppl 2006;4:20.
-
(2006)
Eur J Cancer Suppl
, vol.4
, pp. 20
-
-
Herbst, R.S.1
Fehrenbacher, L.2
Belani, C.P.3
-
95
-
-
33845705108
-
Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors [abstract 3017]
-
Van Cruijsen H, Voest EE, Van Herpen CM, et al. Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors [abstract 3017]. J Clin Oncol 2006;24:3017.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3017
-
-
Van Cruijsen, H.1
Voest, E.E.2
Van Herpen, C.M.3
-
96
-
-
0036531949
-
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
-
Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002;62:1931-4.
-
(2002)
Cancer Res
, vol.62
, pp. 1931-1934
-
-
Rak, J.1
Yu, J.L.2
Kerbel, R.S.3
Coomber, B.L.4
-
97
-
-
0035887463
-
Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo
-
Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
-
(2001)
Cancer Res
, vol.61
, pp. 7501-7506
-
-
Bello, L.1
Carrabba, G.2
Giussani, C.3
-
98
-
-
0037093209
-
Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
-
Man S, Bocci G, Francia G, et al. Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
-
(2002)
Cancer Res
, vol.62
, pp. 2731-2735
-
-
Man, S.1
Bocci, G.2
Francia, G.3
-
99
-
-
2942615257
-
The anti-angiogenic basis of metronomic chemotherapy
-
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
100
-
-
0031753296
-
Treatment of non-small-cell lung cancer with prolonged oral etoposide
-
Kakolyris S, Samonis G, Koukourakis M, et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 1998;21:505-8.
-
(1998)
Am J Clin Oncol
, vol.21
, pp. 505-508
-
-
Kakolyris, S.1
Samonis, G.2
Koukourakis, M.3
-
101
-
-
34247509357
-
Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC) [abstract 7027]
-
Dowlati A, Gray R, Johnson DH, et al. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC) [abstract 7027]. J Clin Oncol 2006;24:7027.
-
(2006)
J Clin Oncol
, vol.24
, pp. 7027
-
-
Dowlati, A.1
Gray, R.2
Johnson, D.H.3
-
102
-
-
34247471304
-
Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer [abstract 150]
-
Koeppen HKW, Ince WL, Holmgren E, et al. Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer [abstract 150]. Eur J Cancer 2004;2:48.
-
(2004)
Eur J Cancer
, vol.2
, pp. 48
-
-
Koeppen, H.K.W.1
Ince, W.L.2
Holmgren, E.3
|